- Home
- SA vs ANIP Comparison
SA vs ANIP Comparison
Compare SA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- ANIP
- Stock Information
- Founded
- SA 1979
- ANIP 2001
- Country
- SA Canada
- ANIP United States
- Employees
- SA N/A
- ANIP N/A
- Industry
- SA Precious Metals
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- SA Basic Materials
- ANIP Health Care
- Exchange
- SA Nasdaq
- ANIP Nasdaq
- Market Cap
- SA 1.1B
- ANIP 1.2B
- IPO Year
- SA N/A
- ANIP N/A
- Fundamental
- Price
- SA $11.29
- ANIP $57.94
- Analyst Decision
- SA
- ANIP Buy
- Analyst Count
- SA 0
- ANIP 7
- Target Price
- SA N/A
- ANIP $77.33
- AVG Volume (30 Days)
- SA 808.0K
- ANIP 172.8K
- Earning Date
- SA 03-28-2025
- ANIP 02-28-2025
- Dividend Yield
- SA N/A
- ANIP N/A
- EPS Growth
- SA N/A
- ANIP N/A
- EPS
- SA N/A
- ANIP N/A
- Revenue
- SA N/A
- ANIP $555,456,000.00
- Revenue This Year
- SA N/A
- ANIP $25.54
- Revenue Next Year
- SA N/A
- ANIP $20.95
- P/E Ratio
- SA N/A
- ANIP N/A
- Revenue Growth
- SA N/A
- ANIP 23.60
- 52 Week Low
- SA $10.87
- ANIP $52.50
- 52 Week High
- SA $20.55
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- SA 40.23
- ANIP 46.25
- Support Level
- SA $11.21
- ANIP $58.37
- Resistance Level
- SA $12.23
- ANIP $60.54
- Average True Range (ATR)
- SA 0.53
- ANIP 1.69
- MACD
- SA -0.12
- ANIP -0.21
- Stochastic Oscillator
- SA 3.43
- ANIP 20.28
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.